Table 3 Multivariate analysis (Cox regression) for the overall survival and leukemia-free survival in MDS patients

From: Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome

Variables

Overall survival

Leukemia-free survival

 

95% CI

  

95% CI

 

RR

Lower

Upper

P-value

RR

Lower

Upper

P-value

Age

1.024

1.014

1.034

<0.001*

0.997

0.983

1.011

0.713

Gender (male vs. female)

1.248

0.922

1.687

0.151

1.251

0.753

2.079

0.387

IPSS-R scoresa

0.306

0.208

0.450

<0.001*

0.211

0.102

0.437

<0.001*

CBL mutation

2.292

1.164

4.513

0.016*

2.561

0.943

6.955

0.065

RUNX1 mutation

1.021

0.679

1.536

0.920

1.381

0.729

2.617

0.322

IDH2 mutation

1.957

1.045

3.665

0.036*

1.798

0.577

5.602

0.311

DNMT3A mutation

1.571

1.028

2.401

0.037*

1.789

0.875

3.658

0.111

TET2 mutation

1.233

0.829

1.835

0.301

1.270

0.642

2.513

0.493

ASXL1 mutation

1.557

1.040

2.329

0.031*

2.009

1.066

3.788

0.031*

EZH2 mutation

1.292

0.724

2.304

0.385

1.413

0.587

3.402

0.440

SRSF2 mutation

1.084

0.684

1.719

0.731

1.168

0.530

2.576

0.700

ZRSR2 mutation

1.212

0.782

1.879

0.389

1.035

0.477

2.249

0.930

Cohesin mutationb

1.232

0.764

1.986

0.392

2.620

1.281

5.359

0.008*

TP53 mutation

9.524

6.067

14.950

<0.001*

14.669

6.664

32.288

<0.001*

  1. RR relative risk, CI confidence interval, IPSS-R revised international prognostic scoring system
  2. *P-value <0.05 was considered significant
  3. aIPSS-R scores: lower IPSS-R scores (very low- and low risk) vs. others
  4. bCohesin genes, including RAD21, STAG1, STAG2, SMC1A, and SMC3A
Back to article page